U.S. antitrust regulators cleared the Pfizer (PFE), Wyeth (WYE) merger
More News related to PFE
- Pfizer Receives FDA Approval For Geodon(R) (Ziprasidone HCI) Capsules For The Adjunctive Maintenance Treatment Of Bipolar Disorder In Adults
- FDA Approves Intravenous Formulation Of Pfizer's Revatio(R) (Sildenafil) For The Treatment Of Pulmonary Arterial Hypertension
- Trading Review for Vivus Inc. Issued by Beacon Equity
- FDA Advisory Committee Finds Data Support the Claim That SPIRIVA(R) HandiHaler(R) Reduces COPD Exacerbations
- Quark Reports Progress of siRNA Clinical Programs; 300 Patients Dosed With Quark Pharmaceuticals' siRNA Drugs In Multiple Fully Enrolled Clinical Trials
More News related to WYE
- Progenics Announces Third Quarter 2009 Financial Results
- Pfizer (PFE) Completes Acquisition of Wyeth (WYE)
- Pfizer Completes Acquisition Of Wyeth
- U.S. antitrust regulators cleared the Pfizer (PFE), Wyeth (WYE) merger
- Progenics Pharma (PGNX) Regains RELISTOR Rights from Wyeth (WYE)
U.S. antitrust regulators cleared the Pfizer (NYSE: PFE), Wyeth (NYSE: WYE) merger.
Related Categories
Mergers and AcquisitionsStocks Mentioned
+0.25Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
